Laporte-Amargos Julia, Sastre Enric, Bergas Alba, Pomares Helena, Paviglianiti Annalisa, Rodriguez-Arias Marisol, Pallares Natalia, Badia-Tejero Ana Maria, Pons-Oltra Paula, Carratalà Jordi, Gudiol Carlota
Infectious Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Pathogens. 2023 Feb 1;12(2):228. doi: 10.3390/pathogens12020228.
: We aimed to assess the incidence, etiology and outcomes of catheter-related bloodstream infection (CRBSI) in onco-hematological patients, to assess the differences between patients with hematological malignancies (HMs) and solid tumors (STs) and to identify the risk factors for Gram-negative (GN) CRBSI. : All consecutive episodes of BSI in adult cancer patients were prospectively collected (2006-2020). The etiology of CRBSI was analyzed in three different 5-year periods. Risk factors for GN CRBSI were assessed in the whole cohort and separately in patients with HMs and STs. : Among 467 episodes of monomicrobial CRBSI, 407 were Gram-positive (GP) (87.1%), 49 GN (10.5%) and 11 fungal (2.4%). Hematological patients (369 episodes) were more frequently neutropenic and were more likely to carry central venous catheters and develop GP CRBSI. Patients with STs (98 episodes) had more comorbidities, more frequently carried port reservoirs and commonly presented more GN CRBSI. GN CRBSI significantly increased over the study period, from 5.2% to 23% ( < 0.001), whereas GP CRBSI decreased from 93.4% to 73.3% ( < 0.001). CRBSI episodes involving port reservoirs and peripherally-inserted central catheters were significantly increased ( < 0.001). The most frequent GPs were coagulase-negative staphylococci (CoNS) (57.8%) and was the most common GN (3%). Multidrug-resistant (MDR) GN represented 32.7% of all GN CRBSIs and increased over time ( = 0.008). The independent risk factors for GN CRBSI in the whole cohort were solid tumor, chronic kidney disease and carrying a port reservoir. Carrying a port reservoir was also a risk factor in patients with STs. Health-care acquisition was identified as a risk factor for GN CRBSI in the whole cohort, as well as in patients with STs and HMs. Inadequate empirical antibiotic treatment (IEAT) occurred regardless of the etiology: 49% for GNs and 48.6% for GPs ( = 0.96). In GP CRBSI, IEAT was mainly due to inadequate coverage against CoNS (87%), whereas in GN CRBSI, IEAT was associated with multidrug resistance (54.2%). Early (48 h and 7-day) and 30-day case-fatality rates were similar when analyzed according to the type of underlying disease and etiology, except for the 30-day case-fatality rate, which was higher in the group of patients with STs compared to those with HMs (21.5% vs. 12.5%, = 0.027). The 48 h case-fatality rate was significantly higher in patients in whom the catheter had not been removed (5.6% vs. 1%; = 0.011), and it remained significant for GP CRBSI (6% vs. 1.3%, = 0.023). : GNs are an increasing cause of CRBSI in cancer patients, particularly in solid tumor patients carrying port reservoirs. Multidrug resistance among GNs is also increasing and is associated with higher rates of IEAT. Decreased 48 h survival was associated with the non-removal of the catheter. These findings should be considered when deciding on early therapeutic management for cancer patients with suspected CRBSI.
我们旨在评估肿瘤血液科患者导管相关血流感染(CRBSI)的发生率、病因及结局,评估血液系统恶性肿瘤(HMs)患者和实体瘤(STs)患者之间的差异,并确定革兰阴性(GN)CRBSI的危险因素。:前瞻性收集了成年癌症患者连续发生的所有血流感染事件(2006 - 2020年)。在三个不同的5年时间段内分析CRBSI的病因。在整个队列中以及分别在HMs患者和STs患者中评估GN CRBSI的危险因素。:在467例单一微生物CRBSI事件中,407例为革兰阳性(GP)(87.1%),49例为GN(10.5%),11例为真菌(2.4%)。血液科患者(369例事件)中性粒细胞减少更为频繁,更有可能携带中心静脉导管并发生GP CRBSI。STs患者(98例事件)有更多合并症,更频繁携带植入式静脉输液港,且通常有更多GN CRBSI。在研究期间,GN CRBSI显著增加,从5.2%增至23%(P < 0.001),而GP CRBSI从93.4%降至73.3%(P < 0.001)。涉及植入式静脉输液港和外周静脉穿刺中心静脉导管的CRBSI事件显著增加(P < 0.001)。最常见的GP是凝固酶阴性葡萄球菌(CoNS)(57.8%),最常见的GN是大肠埃希菌(3%)。多重耐药(MDR)GN占所有GN CRBSI的32.7%,且随时间增加(P = 0.008)。整个队列中GN CRBSI的独立危险因素为实体瘤、慢性肾脏病和携带植入式静脉输液港。携带植入式静脉输液港也是STs患者的危险因素。在整个队列以及STs患者和HMs患者中,医疗护理相关感染被确定为GN CRBSI的危险因素。无论病因如何,均存在经验性抗生素治疗不足(IEAT)的情况:GN为49%,GP为48.6%(P = 0.96)。在GP CRBSI中,IEAT主要是由于对CoNS覆盖不足(87%),而在GN CRBSI中,IEAT与多重耐药相关(54.2%)。根据基础疾病类型和病因分析时,早期(48小时和7天)及30天病死率相似,但STs患者组的30天病死率高于HMs患者组(21.5%对12.5%,P = 0.027)。导管未拔除患者的48小时病死率显著更高(5.6%对1%;P = 0.011),对于GP CRBSI也仍然显著(6%对1.3%,P = 0.023)。:GN是癌症患者CRBSI日益增加的病因,尤其是在携带植入式静脉输液港的实体瘤患者中。GN中的多重耐药也在增加,并与更高的IEAT发生率相关。48小时生存率降低与未拔除导管有关。在为疑似CRBSI的癌症患者决定早期治疗管理时应考虑这些发现。